Literature DB >> 23471234

Endogenous tissue plasminogen activator enhances fibrinolysis and limits thrombus formation in a clinical model of thrombosis.

Andrew J Lucking1, Kyle R Gibson, Elspeth E Paterson, Dana Faratian, Christopher A Ludlam, Nicholas A Boon, Keith A A Fox, David E Newby.   

Abstract

OBJECTIVE: Using a clinical model of deep arterial injury, we assessed the ability of exogenous and endogenous tissue plasminogen activator (t-PA) to limit acute in situ thrombus formation. APPROACH AND
RESULTS: Ex vivo thrombus formation was assessed in the Badimon chamber at low and high shear rates in 2 double-blind randomized cross-over studies of 20 healthy volunteers during extracorporeal administration of recombinant t-PA (0, 40, 200, and 1000 ng/mL) or during endogenous t-PA release stimulated by intra-arterial bradykinin infusion in the presence or absence of oral enalapril. Recombinant t-PA caused a dose-dependent reduction in thrombus area under low and high shear conditions (P<0.001 for all). Intra-arterial bradykinin increased plasma t-PA concentrations in the chamber effluent (P<0.01 for all versus saline) that was quadrupled in the presence of enalapril (P<0.0001 versus placebo). These increases were accompanied by an increase in plasma D-dimer concentration (P<0.005 for all versus saline) and, in the presence of enalapril, a reduction in thrombus area in the low shear (16±5; P=0.03) and a trend toward a reduction in the high shear chamber (13±7%; P=0.07).
CONCLUSIONS: Using a well-characterized clinical model of coronary arterial injury, we demonstrate that endogenous t-PA released from the vascular endothelium enhances fibrinolysis and limits in situ thrombus propagation. These data support a crucial role for the endogenous fibrinolytic system in vivo and suggest that continued exploration and manipulation of its therapeutic potential are warranted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23471234     DOI: 10.1161/ATVBAHA.112.300395

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  4 in total

1.  Impaired endogenous fibrinolytic capacity in prehypertensive men.

Authors:  K J Diehl; B R Weil; J J Greiner; K P Wright; B L Stauffer; C A DeSouza
Journal:  J Hum Hypertens       Date:  2015-01-08       Impact factor: 3.012

2.  Non-invasive in vivo imaging of acute thrombosis: development of a novel factor XIIIa radiotracer.

Authors:  Jack P M Andrews; Christophe Portal; Tashfeen Walton; Mark G Macaskill; Patrick W F Hadoke; Carlos Alcaide Corral; Christophe Lucatelli; Simon Wilson; Ian Wilson; Gillian MacNaught; Marc R Dweck; David E Newby; Adriana A S Tavares
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-06-01       Impact factor: 6.875

3.  Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.

Authors:  Mohammed N Meah; Jennifer Raftis; Simon J Wilson; Vidya Perera; Samira M Garonzik; Bindu Murthy; J Gerry Everlof; Ronald Aronson; Joseph Luettgen; David E Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-09-10       Impact factor: 8.311

4.  Role of Shear Stress and tPA Concentration in the Fibrinolytic Potential of Thrombi.

Authors:  Claire S Whyte; Hadj Ahmed Mostefai; Kim M Baeten; Andrew J Lucking; David E Newby; Nuala A Booth; Nicola J Mutch
Journal:  Int J Mol Sci       Date:  2021-02-20       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.